Status: Recruiting
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).
Participants needed: 186
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Adagene IncUpdated: Jan 7, 2026Locations: 21
Eligibility criteria
≥18 years of age at the time of informed consent. [+7]
Pregnant or breastfeeding females. [+14]